IBD Science for Patients

When you are diagnosed with ulcerative colitis, the exact location of inflammation in your bowel shapes how your condition is managed. When bowel inflammation is confined strictly to the rectum (the final 12 to 15 centimetres of your large intestine), doctors diagnose it as isolated proctitis or ulcerative proctitis. Although proctitis affects roughly 1 in 4 people living with ulcerative colitis, major clinical drug trials have historically excluded proctitis patients, creating a frustrating “evidence gap” in medical science.

Because clinical trials usually focused on broader colitis, doctors often had to adapt general treatment guidelines for proctitis without having large-scale, dedicated real-world data to back up their decisions.

Now, a nationwide study published in the journal Crohn’s & Colitis 360 bridges this gap. By analysing real-world health data from 8,346 patients enrolled in the UK IBD BioResource, researchers have delivered the largest real-world evaluation of proctitis treatments to date, showing which medical strategies bring fast, lasting remission.

Behind the Research: Understanding Proctitis Terms and Real-World Evidence

To understand how doctors evaluate treatment success in isolated proctitis, it helps to look at the clinical terminology and research tools used in the study:

• Isolated Proctitis (E1 Disease): The mildest structural category of ulcerative colitis under the international Montreal Classification. Inflammation is limited strictly to the rectum, causing symptoms like sudden urgency, rectal bleeding, and frequent small bowel movements, while the rest of the colon remains healthy.
• The UK IBD BioResource: A high-tech nationwide research platform funded by the NHS and medical charities. It connects clinical hospital records, health surveys, and genetic samples from over 40,000 IBD patients across the UK, allowing scientists to conduct massive real-world studies.
• Topical vs Oral Therapies: Topical therapies (such as mesalazine suppositories or steroid foams inserted directly into the rectum) deliver medicine directly to the inflamed tissue where it is needed most. Oral therapies (tablets swallowed by mouth) must travel through your stomach and bloodstream to reach your gut wall.
• Disease Extension: A process where inflammation spreads further up the colon over time, expanding from isolated proctitis into left-sided colitis or extensive colitis.
• Advanced Therapies: Modern biological medications (such as anti-TNF drugs, vedolizumab, or ustekinumab) and targeted oral small molecules that turn off specific inflammatory pathways when standard anti-inflammatory drugs are not enough.

Inside the Study: 8,346 Patients Across the UK

This investigation was a large-scale nationwide real-world observational cohort study using data from the UK IBD BioResource across NHS hospital trusts.

The research team analysed treatment journeys for 8,346 adult patients with confirmed isolated proctitis, tracking their health outcomes, prescription records, and disease progression over years of continuous clinical follow-up.

The researchers evaluated how patients responded to initial first-line treatments, how often medication escalation was required, and how many patients experienced disease extension or required surgery.

Key Discoveries: High Success with Local Treatment and Biologic Support

By examining real-world treatment records across thousands of individuals, the researchers uncovered critical insights into proctitis care:

1. Topical 5-ASAs Are the Gold Standard: Direct rectal treatment using mesalazine suppositories proved to be the most effective first-line therapy, achieving high rates of symptom control and stopping inflammation quickly.
2. Combining Topical and Oral Therapy Boosts Success: For patients with stubborn symptoms, combining daily mesalazine suppositories with oral mesalazine tablets delivered significantly higher remission rates than relying on oral tablets alone.
3. Tracking Disease Extension: The study revealed that over long-term follow-up, a minority of patients experienced disease extension (where inflammation spread higher up the colon), highlighting why regular monitoring remains vital even when symptoms feel mild.
4. Biologics Work Effectively for Refractory Proctitis: For patients whose proctitis did not respond to standard 5-ASA drugs or steroids, escalating to advanced biological therapies (such as anti-TNF drugs or vedolizumab) successfully induced remission, proving that modern biologics are highly effective for severe proctitis.
5. Low Surgery Rates: Because proctitis is localised to the rectum, overall surgical colectomy rates remained low across the cohort, particularly when effective topical therapy was started early.

Why This Matters to You as a Patient

If you are managing ulcerative proctitis, this nationwide real-world study provides clear, reassuring direction for your daily care:

1. This Study Proves That Rectal Suppositories Are Your Best First-Line Tool: This study provides evidence that using suppositories or local rectal treatments is not just an optional extra. Delivering medicine directly to your rectum is the single most effective way to calm proctitis inflammation and protect your bowel wall.
2. This Study Shows That Modern Biologics Work When Needed: This study shows that if standard anti-inflammatory suppositories or steroid foams do not fully clear your symptoms, advanced biological therapies offer a proven, effective next step to get your proctitis under control.
3. This Study Provides Evidence That Regular Monitoring Protects You: This study proves that staying in touch with your IBD team and reporting changes in your symptoms ensures that any disease extension is caught early and treated effectively.

By using targeted local treatments and working closely with your specialist team, you can keep proctitis under control and enjoy long-term peace of mind.